Female breast cancer is one of the leading causes of cancer death globally. Clinically, early breast cancer treatment involves a multidisciplinary approach comprising surgery, radiotherapy, and systemic therapy, including chemotherapy. Although early breast cancer is considered curable in a large proportion of patients, chemoresistance remains an important problem. Chemoresistance may result from intrinsic and/or acquired drug resistance. Intrinsic resistance stems from ineffective targeting of the molecular drivers, while acquired resistance occurs in response to drug exposure. During acquired drug resistance, tumors may develop cross-resistance to a series of chemotherapy treatments. Understanding chemoresistance in breast cancer is vital to optimizing existing treatment regimens and improving survival outcomes. The identification of biomarkers that could predict or monitor the response of breast cancer patients to systemic therapy, especially chemotherapy, as well as strategies to overcome chemoresistance in breast cancer is urgently needed.
Therefore, the purpose of this Research Topic is to bring together recent advances in molecular mechanisms involved in resistance to systemic therapies, especially chemoresistance, in breast cancer. We also welcome studies identifying biomarkers predicting or monitoring the response of breast cancer patients to systemic therapy, as well as effective therapeutic targets and novel treatment strategies overcoming resistance to systemic therapy to improve patients' quality of life. We welcome Original Research, Review, Perspective, and Mini-Review on the following aspects:
• Mechanisms involved in resistance to systemic therapy in breast cancer
• Novel biomarkers for resistance to systemic therapy in breast cancer treatment
• In vitro or in vivo models that help understand resistance to systemic therapy in breast cancer
• Emerging strategies for overcoming resistance to systemic therapy in breast cancer and reducing side effects
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Female breast cancer is one of the leading causes of cancer death globally. Clinically, early breast cancer treatment involves a multidisciplinary approach comprising surgery, radiotherapy, and systemic therapy, including chemotherapy. Although early breast cancer is considered curable in a large proportion of patients, chemoresistance remains an important problem. Chemoresistance may result from intrinsic and/or acquired drug resistance. Intrinsic resistance stems from ineffective targeting of the molecular drivers, while acquired resistance occurs in response to drug exposure. During acquired drug resistance, tumors may develop cross-resistance to a series of chemotherapy treatments. Understanding chemoresistance in breast cancer is vital to optimizing existing treatment regimens and improving survival outcomes. The identification of biomarkers that could predict or monitor the response of breast cancer patients to systemic therapy, especially chemotherapy, as well as strategies to overcome chemoresistance in breast cancer is urgently needed.
Therefore, the purpose of this Research Topic is to bring together recent advances in molecular mechanisms involved in resistance to systemic therapies, especially chemoresistance, in breast cancer. We also welcome studies identifying biomarkers predicting or monitoring the response of breast cancer patients to systemic therapy, as well as effective therapeutic targets and novel treatment strategies overcoming resistance to systemic therapy to improve patients' quality of life. We welcome Original Research, Review, Perspective, and Mini-Review on the following aspects:
• Mechanisms involved in resistance to systemic therapy in breast cancer
• Novel biomarkers for resistance to systemic therapy in breast cancer treatment
• In vitro or in vivo models that help understand resistance to systemic therapy in breast cancer
• Emerging strategies for overcoming resistance to systemic therapy in breast cancer and reducing side effects
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
